FG Nexus Inc. (FGF)
Market Closed
20 Oct, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
3. 73
+0.07
+1.91%
$
4.75M Market Cap
7 P/E Ratio
0% Div Yield
2,983,239 Volume
0 Eps
$ 3.66
Previous Close Day Range
3.56 3.93
Year Range
3.43 41.25
Want to track FGF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments
Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis, with positive 96-week phase 2b data published in NEJM. The SYNCHRONY phase 3 program targets a broad MASH population, positioning Akero for significant market opportunity and acquisition interest. GlaxoSmithKline's $1.2B acquisition of FGF21 asset validates the value of Akero's approach and increases likelihood of a strategic buyout occurring.
Seekingalpha | 6 months ago
2025 © Marketlog. All Rights Reserved.
